Letrozole (Femara) - Potent Aromatase Inhibitor — Anabolic Steroids
The most potent third-generation aromatase inhibitor achieving >99% estradiol suppression, FDA-approved for breast cancer, widely used off-label for gynecomastia reversal and ovulation induction.
Overview
Letrozole (Femara) is the most potent third-generation non-steroidal aromatase inhibitor, capable of suppressing circulating estradiol by >99% at the standard 2.5mg daily dose. The BIG 1-98 trial (Breast International Group; n=8,010) demonstrated superiority over tamoxifen in postmenopausal women with HR+ early breast cancer, with improved disease-free survival (HR 0.82), reduced distant metastases, and fewer thromboembolic events. Beyond oncology, letrozole has become a first-line agent for ovulation induction in PCOS (NEJM 2014, n=750: 27.5% live birth rate vs 19.1% for clomiphene, p=0.007). In males, it is used off-label for pubertal gynecomastia reversal and estrogen management during heavy anabolic steroid cycles where maximal aromatase inhibition is required. Due to its extreme potency, over-suppression of estradiol is a significant risk in males, potentially causing joint pain, mood disturbances, and bone density loss. PMID: 19213681, 16236738, 24568029.
Indications
- Adjuvant and extended adjuvant treatment of HR+ early breast cancer in postmenopausal women (FDA-approved; BIG 1-98)
- First-line ovulation induction in polycystic ovary syndrome (PCOS) - off-label but guideline-recommended (ASRM 2017)
- Pubertal and adult gynecomastia reversal in males (off-label)
- Estrogen management during heavy aromatizing anabolic steroid cycles (off-label, bodybuilding use)
- Controlled ovarian hyperstimulation for IVF cycles (off-label)
Mechanism of Action
CYP19 aromatase is the rate-limiting enzyme converting C19 androgens to C18 estrogens in peripheral tissues, ovaries, and intratumoral stroma
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Letrozole (Femara) | 2.5 mg | Once daily | FDA-approved dose for breast cancer; BIG 1-98 trial dose |
| Letrozole | 2.5 mg | Days 3-7 of menstrual cycle | Ovulation induction in PCOS; 5-day protocol per ASRM guidelines |
| Letrozole | 5.0-7.5 mg | Days 3-7 of menstrual cycle | Higher dose for clomiphene-resistant PCOS; increased multiple gestation risk |
| Letrozole | 0.25-0.5 mg | Every other day (EOD) | Off-label male use for estrogen management; titrate based on sensitive E2 assay |
Evidence Grade
GRADE A
Safety & Contraindications
- Most potent AI: >99% estradiol suppression creates high risk of estrogen deficiency symptoms (joint pain, hot flashes, vaginal dryness, osteoporosis)
- Bone mineral density loss: BIG 1-98 showed more fractures vs tamoxifen (9.3% vs 6.5%); calcium and vitamin D supplementation mandatory
- In males, even 0.25mg doses can profoundly suppress estradiol; careful dose titration with laboratory monitoring essential
- Musculoskeletal adverse effects in approximately 25-35% of breast cancer patients; arthralgia may limit treatment adherence
- Potential cardiovascular effects: mixed data on cardiac events; less favorable lipid profile compared to tamoxifen
- Teratogenic: absolutely contraindicated in pregnancy; women of childbearing potential must use effective contraception